MuhammadFurqanMD

Oncology • Iowa City, IA

Head & Neck Cancer, Hematologic Oncology, Thoracic Cancer

Clinical Assistant Professor

Join to view full profile

Dr. Furqan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Furqan's full profile

Already have an account?

Office
200 Hawkins Dr
Dept Of Internal Medicine C-21 GH
Iowa City, IA 52242
Phone+1 319-467-5171

Fax+1 319-353-8383
Is this information wrong?

Education & Training

Westchester Medical CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
Rutgers Health/New Jersey Medical SchoolResidency, Internal Medicine, 2008 - 2011
Dow University of Health SciencesClass of 2005

Certifications & Licensure

IA State Medical License 2014 - 2026
NJ State Medical License 2009 - 2013

Clinical Trials

Pharmacological Ascorbate for Lung Cancer Start of enrollment: 2015 Apr 01
Active, not recruiting
Phase 2
Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer Start of enrollment: 2016 Aug 29
Active, not recruiting
Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
PDR001 + Panobinostat for Melanoma and NSCLC Start of enrollment: 2019 Sep 01
Withdrawn
Phase 1
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2021 Apr 20
Recruiting
Phase 2
Roles: Principal Investigator, Contact, Sponsor-Investigator
Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer Start of enrollment: 2021 Jul 16
Recruiting
Roles: Contact
A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC Start of enrollment: 2018 Nov 16
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2023 Oct 23
Recruiting
Phase 1
Roles: Sponsor-Investigator, Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

8 citations
A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Canc...
Tareq Salous, Nikhil A Shukla, Sandra K Althouse, Susan M Perkins, Muhammad Furqan, Ticiana Leal, Anne M Traynor, Lawrence E Feldman, Nasser H Hanna, Greg A Durm> ;Cancer. 2023 Jan 15
15 citations
Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors.
H Park, G I Shapiro, X Gao, A Mahipal, J Starr, M Furqan, P Singh, A Ahrorov, L Gandhi, A Ghosh, D Hickman, P D Gallacher, A Wennborg, E C Attar, M M Awad, S Das, E E ...> ;ESMO Open. 2022 Oct 1
8 citations
Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer.
Muhammad Furqan, Taher Abu-Hejleh, Laura M Stephens, Stacey M Hartwig, Sarah L Mott, Casey F Pulliam, Michael Petronek, John B Henrich, Melissa A Fath, Jon C Houtman, ...> ;Redox Biology. 2022 Jul 1
3 citations
Pharmacological ascorbate as a novel therapeutic strategy to enhance cancer immunotherapy.
Amira Zaher, Laura M Stephens, Ann M Miller, Stacey M Hartwig, Jeffrey M Stolwijk, Michael S Petronek, Zeb R Zacharias, Thaddeus J Wadas, Varun Monga, Joseph J Cullen,...> ;Frontiers in Immunology. 2022 Jan 1
7 citations
Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer
Bin Qiu, Kaican Cai, Chun Chen, Jun Chen, Ke-Neng Chen, Qi-Xun Chen, Chao Cheng, Tian-Yang Dai, Junqiang Fan, Zhaohui Fan, Jian Hu, Wei-Dong Hu, Yun-Chao Huang, Gening...> ;Translational Lung Cancer Research. 2021 Sep 1
1 citations
Time to put it out - nurse-facilitated tobacco treatment in a comprehensive cancer center.
David A. Katz, Sarah L. Mott, Jane A Utech, Autumn C Bahlmann, Kimberly A Dukes, Aaron T Seaman, Douglas E Laux, Muhammad Furqan, Zachary J Pollock, Mark W. Vander Weg> ;Translational Behavioral Medicine. 2021 Sep 15
4 citations
Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a STK11 mutation.
Josiah An, Melissa Yan, Nanmeng Yu, Adithya Chennamadhavuni, Muhammad Furqan, Sarah L. Mott, Bradley T. Loeffler, Tim J. Kruser, Timothy L. Sita, Lawrence Eric Feldman...> ;Translational Lung Cancer Research. 2021 Aug 1
31 citations
Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer
Justin Chau, Meeta Yadav, Ben Liu, Muhammad Furqan, Qun Dai, Shailesh K. Shahi, Arnav Gupta, Keri Nace Mercer, Evan Eastman, Taher Abu Hejleh, Carlos H. F. Chan, Georg...> ;BMC Cancer. 2021 Jul 13
5 citations
Narrative review: mesenchymal-epithelial transition inhibitors—meeting their target
Danish Safi, Taher Abu Hejleh, Muhammad Furqan> ;Translational Lung Cancer Research. 2021 Jan 1
10 citations
Magnetic resonance imaging (MRI) of pharmacological ascorbate-induced iron redox state as a biomarker in subjects undergoing radio-chemotherapy.
Cameron Cushing, Michael S. Petronek, Kellie L. Bodeker, Sandy Vollstedt, Heather Brown, Emyleigh Opat, Nancy J. Hollenbeck, Thomas Shanks, Daniel J. Berg, Brian J. Sm...> ;Redox Biology. 2021 Jan 1
53 citations
The clinical significance of soluble PD-1 and PD-L1 in lung cancer.
Taher Abu Hejleh, Muhammad Furqan, Zuhair K. Ballas, Gerald H. Clamon> ;Critical Reviews in Oncology/hematology. 2019 Nov 1
4 citations
Comparing high-dose cisplatin with cisplatin-based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous...
Muhammad Furqan, Travis Snyders, Mohammed U Saqlain, Sarah L. Mott, Douglas Earl Laux, Anthony N. Snow, Carryn M. Anderson, J.M. Watkins, Gerald H. Clamon> ;Cancer Medicine. 2019 Apr 9
10 citations
Association of Hemophagocytic Lymphohistiocytosis and Programmed Death 1 Checkpoint Inhibitors.
Behnam Laderian, Kelly Koehn, Carol J. Holman, Laurel Lyckholm, Muhammad Furqan> ;Journal of Thoracic Oncology. 2019 Apr 1
16 citations
Lobar versus sub-lobar surgery for pulmonary typical carcinoid, a population-based analysis
Muhammad Furqan, Tien Yy, Schroeder Mc, Kalpaj R. Parekh, John Keech, Bryan G. Allen, Alexandra Thomas, Jun Zhang, Gerald H. Clamon, Abu Hejleh T> ;Journal of Thoracic Disease. 2018 Sep 10
Screening Patients with Esophageal Cancer to Determine Eligibility for Adjuvant Treatment Trials.
Taher Abu Hejleh, Laith Abushahin, John Keech, Bryan G. Allen, Kalpaj R. Parekh, Muhammad Furqan, Mark D. Iannettoni, Gideon K D Zamba, Sarah L. Mott, Gerald H. Clamon> ;Anticancer Research. 2018 Sep 1
9 citations
Atezolizumab after Nivolumab-Induced Inflammatory Polyarthritis: Can Anti-PD-L1 Immunotherapy Be Administered after Anti-PD-1-Related Immune Toxicities?
Umang Swami, Petar Lenert, Muhammad Furqan, Taher Abu Hejleh, Gerald H. Clamon, Jun Zhang> ;Journal of Thoracic Oncology. 2018 Jun 1
3 citations
Learning about facts of life: perspective from medical students on sources and preferences about puberty and sex education in Karachi.
Masood Ali Shaikh, Syed Muhammand Mubeen, Muhammad Furqan> ;JPMA. the Journal of the Pakistan Medical Association. 2017 Nov 1
23 citations
Mitochondrial Superoxide Increases Age-Associated Susceptibility of Human Dermal Fibroblasts to Radiation and Chemotherapy.
Kranti A. Mapuskar, Kyle H. Flippo, Joshua D. Schoenfeld, Dennis P. Riley, Stefan Strack, Taher Abu Hejleh, Muhammad Furqan, Varun Monga, Frederick E. Domann, John M. ...> ;Cancer Research. 2017 Sep 15
95 citations
Erratum: O2 ⋅− and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate (Cancer ...
Joshua D. Schoenfeld, Zita A. Sibenaller, Kranti A. Mapuskar, Brett A. Wagner, Kimberly L. Cramer-Morales, Muhammad Furqan, Sonia Sandhu, Thomas L. Carlisle, Mark C. S...> ;Cancer Cell. 2017 Aug 14
90 citations
Oand HO-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate.
Joshua D Schoenfeld, Zita A Sibenaller, Kranti A Mapuskar, Brett A Wagner, Kimberly L Cramer-Morales, Muhammad Furqan, Sonia Sandhu, Thomas L Carlisle, Mark C Smith, T...> ;Cancer Cell. 2017 Apr 10
1 citations
A Single-Institution Analysis of Thymic Carcinoma Treated with Multi-Modality Therapy.
I. Mohiuddin, Muhammad Furqan, Gerald H. Clamon, John Keech, Carryn M. Anderson, Mark C. Smith, John M. Buatti, Bryan G. Allen> ;Annals of Radiation Therapy and Oncology. 2017 Nov 22
Once Daily High-dose Radiation (≥60 Gy) Treatment in Limited Stage Small Cell Lung Cancer.
Amir Zahra, Tangel Chang, Taher Abu Hejleh, Muhammad Furqan, Gerald H. Clamon, Sudershan K. Bhatia, J.M. Watkins, Sarah L. Mott, Logan Ahmann, Kellie L. Bodeker, Dougl...> ;Journal of Oncology Translational Research. 2017 Jan 1
2 citations
Air leakage in multiple compartments after endoscopy.
Amanda Grippen Goddard, Bryan C. McConomy, Girish Bathla, Muhammad Furqan, William B. Silverman> ;Cleveland Clinic Journal of Medicine. 2016 Oct 1
3 citations
The Conundrum of "Warfarin Hypersensitivity": Prolonged Partial Thromboplastin Time From Factor IX Propeptide Mutation
Arunabh Sekhri, Adriana Lisinschi, Muhammad Furqan, Chandrasekar Palaniswamy, Nikhil Mukhi, Ridhi Gupta, John C. Nelson> ;American Journal of Therapeutics. 2016 May 1
25 citations
Novel agents for advanced pancreatic cancer
Akintunde Akinleye, Chaitanya Iragavarapu, Muhammad Furqan, Shundong Cang, Delong Liu> ;Oncotarget. 2015 Jun 2
Join now to see all

Abstracts/Posters

[Board 555] Effect of Anakinra on Colchicine Resistant and Steroid Dependent Recurrent Pericarditis: A Systemic Review and Meta-Analysis
Muhammad Furqan, 2019 ACC Scientific Session & Expo, New Orleans, New Orleans, 3/18/2019